<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q/A
AMENDMENT #1
================================================================================
(Mark One)
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
--- EXCHANGE ACT OF 1934
For the quarterly period ended October 1, 1993
OR
--- TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____________________
TO ___________________________
Commission File No. 0-12744
SUNRISE MEDICAL INC.
(Exact name of registrant as specified in its charter)
Delaware 95-3836867
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
2382 FARADAY AVENUE, SUITE 200
CARLSBAD, CA 92008
(Address of principal executive offices)
Registrant's telephone number, including area code: (619) 930-1500
Indicate by check mark whether registrant (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months and (2) has been subject to such filing requirements for
the past 90 days. Yes X No
----- -----
Number of shares of common stock outstanding at November 5, 1993: 17,723,379
<PAGE>
SUNRISE MEDICAL INC.
PART 1--FINANCIAL INFORMATION
The company has restated previously issued financial results for the fiscal
years ended June 30, 1995 and July 1, 1994 following an internal investigation
that determined that accounting and financial reporting practices at its Bio
Clinic subsidiary were erroneous in numerous respects, resulting in the
overstatement of revenue, income and assets and the understatement of
liabilities. Because it is not practicable to reconstruct reliable accounting
records at Bio Clinic for interim periods during those years, the company has
been unable to allocate accurately to individual quarters the full-year
restatement adjustments for any financial statement item other than net sales.
Accordingly, the company has withdrawn its previously reported quarterly results
for the thirteen-week period ended October 1, 1993, and these previously
reported results should be disregarded. Reference is made to the company's Form
10-K/A Amendment No. 1 to Annual Report for the fiscal year ended June 30, 1995
for additional information.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
SUNRISE MEDICAL INC.
Date: February 21, 1996 /s/ Ted N. Tarbet
-------------------------------
Ted N. Tarbet
Senior Vice President and
Chief Financial Officer
(Principal Financial Officer)
Date: February 21, 1996 /s/ John M. Radak
-------------------------------
John M. Radak
Vice President and Controller
(Principal Accounting Officer)
2
